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Abstract
Background: Numerous medications should be avoided, or require dose adjustment in subjects with impaired
kidney function. We aimed to assess the prevalence of potentially inappropriate use of renal risk drugs in a nation-
wide, community-dwelling Polish older adult population.
Methods: We analysed regular intake of 38 medications that should be avoided, requiring dose modification, increase
the risk of pre-renal kidney injury, or may cause potassium retention in subjects with moderately to severely impaired
renal function in the PolSenior data base (N = 4514, mean age 76 ± 11 yrs). Kidney function was assessed with short
Modification of Diet in Renal Disease formula estimated glomerular filtration rate (sMDRD) and Cockcroft-Gault creatinine
clearance (CC).
Results: There were 855 (19%) individuals with sMDRD < 60 ml/min/1.73m2, and 1734 (38%) with CC < 60 ml/min.
Among drugs that should be avoided, spironolactone (20.4% of patients as classified by sMDRD and 17.5% by CC)
, non-steroidal anti-inflammatory drugs (13.4 and 11.3%), hydrochlorothiazide (11.1 and 11.0%), and metformin (6.
9 and 8.2%) were most frequently used. The most frequently used drugs requiring dose modification were
piracetam (13.9% by sMDRD, and 11.9% by CC), digoxin (8.3 and 8.8%), and gliclazide (6.8 and 5.9%). Classification
of a drug use as ‘appropriate’ or ‘inappropriate’ was discordant depending on the method of kidney function
assessment (sMDRD or CC) in up to 30%.
Subgroups with sMDRD < 60 ml/min/1.73m2 and with CC < 60 ml/min were taking ≥2 drugs increasing the risk
of pre-renal kidney injury more frequently than individuals with better kidney function (46.6 vs. 23.1 and 33.0% vs.
24.4%, respectively).
There were 24.7% of individuals with sMDRD < 60 ml/min/1.73m2 and 18.0% with CC < 60 ml/min taking 2 or
more drugs increasing serum potassium level. The proportion of subjects with hyperkalaemia increased with the
number of such drugs.
Conclusions: Use of drugs that should be avoided or require dose adjustment due to renal impairment, and potentially
inappropriate drug combinations is a common problem in older adults in Poland. Assessment of kidney function with
sMDRD may result in overlooking of requirements for dose adjustment formulated based on creatinine clearance.
Trial registration: Not applicable.
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Background
Chronic kidney disease (CKD) is a common entity
among older adult subjects. After the age of 40, kidney
function assessed with creatinine clearance decreases by
8–9 ml/min with each decade of life [1, 2]. This decrease
results from a normal biological process of aging and
superimposing diseases, such as diabetes and hyperten-
sion [3]. The prevalence of CKD in the general popula-
tion is estimated at approximately 11% [4–6] and
increases with age reaching 45% in subjects aged 80
years or more [7, 8].
Numerous medications commonly used in the older
adults should be avoided in subjects with impaired kidney
function because of their nephrotoxic properties, e.g.,
non-steroidal anti-inflammatory drugs (NSAIDs),
angiotensin-converting enzyme inhibitors (ACEI), metho-
trexate, loop and thiazide diuretics, ranitidine, some antibi-
otics [8]. Other drugs, e.g., digoxin, gliclazide, and atenolol
are excreted by the kidney and require dose adjustment in
subjects with impaired kidney function [9]. The process of
drug selection and dose-adjustment is particularly challen-
ging in the older population, because of common comorbid-
ity and associated polypharmacy [10]. Incidences of adverse
drug reactions in patients with renal impairment are higher
than in subjects with normal kidney function [11]. In the
GIFA study (Gruppo Italiano di Farmacovigilanza nell’An-
ziano; the Italian Group of Farmacoepidemiology in the Eld-
erly) low estimated glomerular filtration rate (eGFR) or
creatinine clearance were significantly more prevalent in
hospitalized elderly patients with adverse reactions caused
by hydrosoluble drugs, esp. diuretics, digoxin,
angiotensin-converting enzyme inhibitors (ACEI), and anti-
hyperglycemic agents [12]. Adverse drug reactions often re-
sult from errors in prescribing or the lack of dose
adjustment [13]. Despite the recognized importance of in-
appropriate drug prescriptions in older adults with CKD,
the appropriate choice of medication and dosage adjustment
are often neglected in daily clinical practice. Partially it is
caused by utilization of eGFR provided by laboratories along
with serum concentration of creatinine, calculated according
to the short Modification of Diet in Renal Disease (sMDRD),
or the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) formulas, and skipping calculation of
Cockcroft-Gault creatinine clearance (CC) used in drug
registration process and required for dose adjustment.
Several studies have shown that the prevalence of in-
appropriate prescriptions in hospitalized older adults
with renal impairment varies from 9 to 67% [14–19]. Re-
gardless of the fact that in older adults with CKD most
drugs are prescribed in an outpatient setting, few studies
have investigated the problem of inappropriate drug use
in this population. In a recent systematic review, Dorks
et al. [20] have identified the lack of dose adjustment for
renal function as a common problem, ranging from 6 to
43% of inappropriate prescriptions in nursing homes
and 1–37% in outpatient settings. Of note, only four
studies included in the review [21–24] were large,
population-based analysis. The authors of the review
emphasized the importance of further investigation in
this field.
Aim
We analyzed the PolSenior database to assess the preva-
lence of regular intake of renal risk drugs (defined as
medications that should be avoided, or that require dose
adjustment in subjects with impaired kidney function) in
the community-dwelling Polish older adult population.
Additionally, we assessed the prevalence of potentially
inappropriate drug combinations in such individuals.
Methods
We retrospectively analyzed data from the PolSenior
study, a multidisciplinary research project, conducted in
2007–2011, to assess the medical, psychological, social
and economic aspects of aging in Poland. Participants
were selected through a multi-stage draw, planned to
obtain a sample representative for Polish old population.
A detailed description of the study design has already
been presented elsewhere [25].
Renal function was assessed with glomerular filtration
rate calculated with the short Modification of Diet in
Renal Disease formula (sMDRD) [26] as serum creatin-
ine concentrations were measured using the Jaffe
method (modular PPE, Roche Diagnostics GmbH,
Mannheim, Germany), and creatinine clearance (CC)
calculated with the Cockcroft-Gault formula [27].
We analyzed regular (≥ 3 times per week) intake of
medications that should be avoided, or requiring dose
modification when used in subjects with moderately
(eGFR < 50–60 ml/min) to severely (eGFR < 25–30ml/
min) impaired renal function. The selection of drugs
chosen for analysis was based on guidelines from the
American Geriatrics Society [28] and consensus guide-
lines for oral dosing of primarily renally cleared medica-
tions in older adults by Hanlon et al. [29]. Additionally,
several medications commonly used in older patients
were analyzed based on information given by Ashley et
al. [9]. Only drugs registered in Poland were assessed. Fi-
nally, 38 drugs were selected for analysis (Tab. 1). For
each drug, the number and percentage of subjects taking
it in the total study population were calculated. Next,
the number and percentage of given drug users among
individuals with kidney function below and above the
level indicated in the guidelines (Tab. 1) were calculated
and classified as potentially inappropriate use and renally
appropriate use. Calculations were performed for both
creatinine clearance calculated with the Cockcroft-Gault
formula and sMDRD-derived eGFR. In the same
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manner, we analyzed potentially inappropriate combina-
tions of drugs:
1) concomitant use of drugs that increase the risk of
pre-renal kidney injury [combination of nonsteroidal
anti-inflammatory drugs (NSAIDs), diuretics, ACEI, and
angiotensin II receptor blockers (ARB)],
2) combination of drugs resulting in potassium retention
(ACEI, ARB, aldosterone antagonists, potassium-sparing di-
uretics, and potassium-containing agents).
Statistical analysis
Statistical analysis was performed with StatSoft Statistica
v12. Data are shown as mean ± standard deviation or
numbers (%). Percentage of particular drug users among
subjects with eGFR and CC below and above the level
indicated in the recommendations was compared with
the chi2 test with Yates correction (if appropriate). For
potentially inappropriate drug combinations, we per-
formed comparisons between patients with eGFR or CC
below and above 60ml/min/1.73m2 or 60ml/min, re-
spectively. P value < 0.05 was considered significant.
Results
Data concerning 5695 subjects were included in the Pol-
Senior database. After exclusion of 1181 subjects in
whom blood samples were not drown for serum creatin-
ine assessment or anthropometric data were missing,
data on 4514 (79.3%) subjects [2177 (48.2%) women]
were included in the analysis. The mean age was 76 ± 11
yrs.
Among study group, 855 participants had CKD stage
3–5 (staging according to the National Kidney Founda-
tion classification is presented in Table 2) [30]. The
mean sMDRD was 78.3 ± 22.6 ml/min/1.73m2 and CC
was 79.5 ± 29.1 ml/min.
Of 4514 individuals in the study group, 1916 (42.4%)
subjects were regularly taking at least one of 38 analyzed
drugs. Among individuals with sMDRD and CC below
60ml/min/1.73m2 and ml/min, the prevalence of poten-
tially inappropriate drug use was 41.2 and 36.8%, re-
spectively. In subjects with sMDRD and CC below 30
ml/min/1.73m2 and ml/min, the prevalence was 58.2
and 57.7%.
Table 1 List of drugs chosen for analysis and prescription
recommendations in patients with impaired renal function
Name of drug Recommendations Reference
Gastrointestinal drugs
Metoclopramide Avoid < 40 ml/min 28
Famotidine Reduce dose < 50 ml/min 27,28
Ranitidine Reduce dose < 50 ml/min 27,28
Antidiabetics
Metformin Avoid < 60 ml/min 28
Acarbose Avoid < 25 ml/min 9
Gliclazide Reduce dose < 50 ml/min 9
Antithrombotic agents
Dabigatran Avoid < 30 ml/min 27
Rivaroxaban Reduce dose < 50 ml/min 27
Rivaroxaban Avoid < 30 ml/min 27
Enoxaparin Reduce dose < 30 ml/min 27
Cardiovascular drugs
Digoxin Reduce dose < 50 ml/min 9
Sotalol Avoid < 40 ml/min 28
Atenolol Reduce dose < 35 ml/min 28
Amiloride Avoid < 30 ml/min 27
Spironolactone Avoid < 30 ml/min 27
Hydrochlorothiazide Avoid < 30 ml/min 27
Rosuvastatin Reduce dose < 60 ml/min 9
Fenofibrate Reduce dose < 60 ml/min 9
Antianalgesics
Tramadol Reduce dose < 30 ml/min 27
Morphine Reduce dose < 50 ml/min 9
Oxycodone Reduce dose < 50 ml/min 9
NSAIDs Avoid < 50 ml/min 9
Antidepressants
Duloxetine Avoid < 30 ml/min 27
Bupropion Reduce dose < 50 ml/min 9
Venlafaxine Reduce dose < 30 ml/min 9
Anti-epileptic drugs
Gabapentin Reduce dose < 60 ml/min 27,28
Pregabalin Reduce dose < 60 ml/min 27
Levetiracetam Reduce dose < 80 ml/min 9,27
Topiramate Reduce dose < 70 ml/min 27
Other drugs
Piracetam Reduce dose < 50 ml/min 9
Risperidone Reduce dose < 50 ml/min 9
Sulpiride Reduce dose < 50 ml/min 9
Cetirizine Reduce dose < 30 ml/min 28
Fexofenadine Reduce dose < 80 ml/min 28
Tizanidine Reduce dose < 25 ml/min 9
Table 1 List of drugs chosen for analysis and prescription
recommendations in patients with impaired renal function
(Continued)
Name of drug Recommendations Reference
Colchicine Reduce dose < 30 ml/min 27
Alendronic acid Avoid < 35 ml/min 9
Methotrexate Reduce dose < 50 ml/min 9
Memantine Reduce dose < 30 ml/min 9,28
NSAIDs Nonsteroidal anti-inflammatory drugs
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Detailed data concerning the use of renal risk drugs in
subjects with the renal function below and above the
level indicated in the recommendations (potentially in-
appropriate use and renally appropriate use) is presented
in Table 3. Twenty-one drugs were taken only occasion-
ally (in less than 20 individuals), and they are not shown
in Table 3 for clarity reasons (bupropion, colchicine,
dabigatran, duloxetine, enoxaparin, famotidine, fexofena-
dine, gabapentin, levetiracetam, memantine, methotrex-
ate, morphine, oxycodone, pregabalin, risperidone,
rivaroxaban, rosuvastatin, sulpiride, tizanidine, topira-
mate, and venlafaxine).
Among medications that should be avoided, spironolac-
tone (prevalence of potentially inappropriate use 17.5% by
CC, and 20.4% by sMDRD), NSAIDs (11.3 and 13.4%), hy-
drochlorothiazide (11.0 and 11.1%), metformin (8.2 and
6.9%), and amiloride (6.4 and 4.3%) were most frequently
used. The most frequently used drugs requiring dose
modification at given level of renal impairment were pir-
acetam (prevalence of potentially inappropriate use 11.9%
by CC, and 13.9% by sMDRD), digoxin (8.8 and 8.3%), gli-
clazide (5.9 and 6.8%), and ranitidine (3.9 and 3.7%).
We identified individuals taking a combination of two
or more drugs increasing the risk of pre-renal impair-
ment of kidney function (diuretics + NSAIDs + ACEI or
ARB) (Table 4). In the total population, 1251 (27.7%) of
subjects were taking 2–5 of such drugs. Intake of two or
more drugs was more frequent in patients with CKD
stage 3–5 as compared with subjects with better kidney
function, despite the method of kidney function evalu-
ation (CC: 33.0% of patients vs. 24.4%, p < 0.05; sMDRD:
46.6 vs. 23.1%, p < 0.05). Combinations of ACEI/ARB
and diuretics were more prevalent in subjects with CC
< 60 ml/min or sMDRD < 60ml/min/1.73m2 as com-
pared to individuals with better kidney function. Combi-
nations of NSAIDS and diuretics, as well as triple
combinations, were more frequently used by subjects
with sMDRD < 60ml/min/1.73m2 as compared to those
with higher sMDRD.
We also identified individuals taking a combination of 2
or more drugs that may result in hyperkalaemia (ACEI,
ARB, aldosterone antagonist, potassium-sparing diuretics,
potassium-containing agents) (Table 5). Regardless of the
method of kidney function assessment, subjects with CKD
stage 3–5 were taking ≥2 drugs increasing potassium level
more frequently than subjects with better kidney function
(sMDRD: 18.1 vs. 10.9%, p < 0.05; CC: 24.7 vs. 11.0%, p <
0.05). The prevalence of hyperkalaemia in subjects taking
1, 2 or 3 drugs was higher in subjects with CC or sMDRD
< 60ml/min/1.73m2 as compared to those with better kid-
ney function (Table 6). Chi-square test for trend showed
that the proportion of subjects with hyperkalaemia in-
creased significantly with the number of drugs in three of
four analyzed subgroups: subjects with CC < 60ml/min,
individuals with CC ≥ 60ml/min, and a subgroup with
sMDRD < 60ml/min/1.73m2.
The prevalence of potentially inappropriate use of
some drugs and drug combinations varied depending on
the method of assessment of kidney function (Table
3-6). We identified subjects in whom sMDRD values
were higher than indicated in the recommendations for
a particular drug (renally appropriate use), but CC values
were below this threshold (potentially inappropriate use;
Table 3, last column). Discordant evaluation of ‘appro-
priateness’ of use ranged from 0 to 30%, and was highest
for digoxin (30.9%), ranitidine (28.0%), and piracetam
(22.5%).
Discussion
In this analysis of the national, population-based PolSenior
study, we assessed the use of renal risk drugs, i. e. drugs
that should be avoided and medications requiring dose re-
duction in subjects with impaired renal function. We found
that approximately 40% of subjects with CKD stage 3, and
nearly 60% of individuals with CKD stage 4 and 5 were tak-
ing at least one medication that was contraindicated given
their level of renal function, or for which there were renal
dosing recommendations. The results of previous reports
on the use of renal risk drugs in subjects with CKD vary
widely, from 13.3% in the Three-City population-based
study [21], 30–53% in large cohort of outpatient older adult
subjects [22], up to 62% in a series of hospitalized patients
[18] and 80.5% in a small Turkish study [31]. Comparison
between results of these studies, as well as with the results
of studies revised by Dorks et al. [20] should be made with
caution because of various drug sets analyzed in each re-
port, and different definitions of potentially inappropriate
drug use in CKD patients. Although we have not analyzed
if doses of drugs requiring modification actually exceeded
the maximum recommended daily dose in patients with
given level of kidney impairment, the high percentage of
subjects with CKD stage 3–5 taking renal risk drugs indi-
cates increased the risk of drug-related problems [18] and
all-cause mortality [21].
The most frequently used drugs that should be
avoided in patients with renal impairment were diuretics
Table 2 Renal function staged using the National Kidney
Foundation classification (total number of subjects = 4514)
CKD stage sMDRD (ml/min/1.73m2) CC (ml/min)
1 (eGFR ≥90); n (%) 1206 (26.7) 1048 (23.2)
2 (eGFR 60–89); n (%) 2453 (54.3) 1732 (38.4)
3 (eGFR 30–59); n (%) 800 (17.7) 1533 (34.0)
4 (eGFR 15–29); n (%) 50 (1.1) 187 (4.1)
5 (eGFR < 15); n (%) 5 (0.1) 14 (0.3)
sMDRD short Modification of Diet in Renal Disease study equation; CC
Creatinine clearance calculated with Cockcroft-Gault; CKD Chronic
kidney disease
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(spironolactone, hydrochlorothiazide, and amiloride),
NSAIDs, and metformin. The most frequently used
medications requiring dose adjustment were piracetam,
digoxin, gliclazide and ranitidine (Table 3). While
NSAIDs, metformin, diuretics, and ranitidine are fre-
quently reported as being inappropriately prescribed
in patients with renal impairment [20], high propor-
tions of subjects taking digoxin and piracetam are
surprising. The possible explanation is that neither di-
goxin nor piracetam is listed by Beers criteria [28] or
consensus guidelines by Hanlon et al. [29]. Digoxin
was excluded from some studies, as an assessment of
serum concentrations and therapeutic response is im-
portant for the evaluation of ‘appropriateness’ of its
use [16]. We included these drugs in our analysis
based on their frequent use in the total PolSenior
population and well-established recommendations for
dose adjustment in CKD [9]. It should be emphasized
that indications for their use have been limited since
the time the PolSenior study was conducted, and thus
the prevalence of inappropriate use of these drugs
presumably should have diminished. For metformin,
we used the restrictive recommendations to avoid its
use if CC was below 60 ml/min [29]. Although such a
threshold can be still found in product characteristics
of metformin, some recent guidelines [32–34]
recommend cautious continuation of its use in pa-
tients with CC above 30 ml/min. Such a change in
recommendations would greatly influence the preva-
lence of potentially inappropriate prescriptions.
Comparison of prevalence of renal risk drug intake in
subjects with kidney function below and above the level
indicated in recommendations revealed that metformin
was the only drug that was used less frequently in sub-
jects with renal contraindications (Tab. 3). The preva-
lence of intake of the remaining drugs with renal
recommendations did not differ between these groups of
patients or was even higher in subjects with kidney func-
tion below the recommended level (esp. ranitidine,
digoxin, spironolactone, and piracetam). The percent of
subjects in whom the use of a renal risk drug was poten-
tially inappropriate among all subjects taking this par-
ticular medication ranged from 0 to 46%, and was
highest for digoxin, piracetam, fenofibrate, and raniti-
dine. These data should be interpreted with caution, as
CKD is associated with numerous chronic conditions,
including hypertension, congestive heart failure, atrial
fibrillation, and diabetes [35–38], which may explain
why subjects with CKD stage 3–5 frequently received di-
uretics, digoxin, metformin, or piracetam – a nootropic
drug commonly prescribed for cognitive impairment and
dementia despite its unproven efficacy [39]. Neverthe-
less, the widespread use of medications with renal rec-
ommendations in PolSenior subjects with impaired
kidney function suggests that the prescribers’ adherence
to these recommendations was poor. In addition, it may
Table 4 Subjects taking drugs increasing risk of pre-renal impairment of kidney function (nonsteroidal anti-inflammatory drugs +
angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers + diuretics)
Drug combinations Total
population
(n = 4514)
CC sMDRD
< 60ml/min
(n = 1734)
≥ 60 ml/min
(n = 2780)
< 60ml/min/1.73m2
(n = 855)
≥ 60 ml/min/1.73m2
(n = 3659)
ACEI/ARB + diuretic; n (%) 840 (16.61) 391 (22.55)* 449 (16.15) 278 (32.51)# 562 (15.36)
ACEI/ARB + NSAID; n (%) 225 (4.56) 86 (4.59) 139 (5.00) 50 (5.85) 175 (4.78)
Diuretic + NSAID; n (%) 163 (3.61) 71 (4.09) 92 (3.31) 54 (6.32)# 109 (2.98)
ACEI/ARB + diuretic + NSAID; n (%) 98 (2.17) 39 (2.25) 59 (2.11) 31 (3.63)# 67 (1.83)
*p < 0.05 vs. patients with CC ≥ 60ml/min
#p < 0.05 vs. patients with sMDRD ≥60 ml/min/1.73m2
ACEI Angiotensin-converting enzyme inhibitor; sMDRD = short Modification of Diet in Renal Disease study equation; ARB = angiotensin II receptor blocker; CC =
creatinine clearance; NSAID = nonsteroidal anti-inflammatory drug
Table 5 Concomitant use of drugs increasing serum potassium level (angiotensin-converting enzyme inhibitors + angiotensin II
receptor blockers + aldosterone antagonists + potassium-sparing diuretics + potassium-containing agents)
No. of drugs Total
population
(n = 4514)
CC sMDRD
< 60ml/min
(n = 1734)
≥ 60ml/min
(n = 2780)
< 60 ml/min/1.73m2
(n = 855)
≥ 60 ml/min/1.73m2
(n = 3659)
1 drug; n (%) of patients 1621 (35.91) 669 (38.58) 952 (34.24) 391 (45.73) 1230 (33.62)
2 drugs; n (%) of patients 506 (11.21) 258 (14.88) 248 (8.92) 180 (21.05) 326 (8.91)
3 drugs; n (%) of patients 105 (2.33) 54 (3.11) 51 (1.83) 30 (3.51) 75 (2.05)
4 drugs; n (%) of patients 4 (0.09) 1 (0.06) 3 (0.11) 1 (0.12) 3 (0.08)
sMDRD = short Modification of Diet in Renal Disease study equation; CC Creatinine clearance calculated with Cockcroft-Gault formula
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be caused by the lack of CC calculation and taking into
consideration only eGFR provided by laboratories, when
prescribing drugs.
It has been recognized that concurrent use of ACEI/
ARB and diuretics with NSAIDs is associated with in-
creased risk of renal adverse effects, particularly in the
older adults [40]. Each of these drugs may cause
pre-renal injury via different mechanisms: diuretics may
cause hypovolaemia and reduce plasma flow, ACEI/ARB
lead to efferent arteriolar vasodilation and reduce
glomerular filtration rate, and NSAIDs inhibit
prostaglandin-induced afferent arteriolar vasodilatation
[40]. Patients taking 2 or 3 drugs from the groups above
were found to have elevated creatinine levels [41], and
the use of triple therapy (but not double therapy) was
associated with 31% higher risk of acute renal failure
[42]. Therefore, such combinations should be avoided,
especially in the older adults. The prevalence of triple
therapy in the PolSenior population was rather low, as
compared to that reported by Loboz and Shenfield (2.2
vs. 6.3%), and the prevalence of double therapy was
somewhat higher (24.8 vs. 19.9%) [41]. Importantly, the
percentage of subjects receiving such combinations
among patients with CKD stage ≥3 was similar to, or
higher than in individuals with better kidney function
(Table 4).
Hyperkalaemia is a common drug-related problem, es-
pecially in the older adults, in patients with moderate to
severe CKD, and those taking combinations of drugs
known to increase serum potassium levels [43]. Concur-
rent use of aldosterone antagonists and potassium con-
serving drugs without monitoring of serum potassium
has been included in the modified STOPP criteria [44].
Over 13% of subjects in the PolSenior population was
taking concurrently 2–3 drugs increasing serum potas-
sium, and the prevalence of concomitant use of such
drugs was higher in individuals with CKD stage ≥3
(Table 5). The prevalence of hyperkalaemia increased
with the number of drugs taken, and was higher in sub-
jects with moderate to severe CKD (reaching 62% in
individuals with sMDRD < 60ml/min/1.73m2 receiving 3
drugs). These findings indicate that potentially inappro-
priate combinations of drugs are prescribed without tak-
ing into consideration renal risk, and/or that renal
function and serum potassium are not adequately moni-
tored while using such combined therapy.
The prevalence of use of renal risk drugs and poten-
tially inappropriate drug combinations differed depend-
ing on the method of assessment of kidney function (CC
or sMDRD; Tables 3-6). For some drugs with the recom-
mendation at the sMDRD level of 50–60ml/min/
1.73m2, e.g., piracetam, digoxin, or ranitidine, in 20 to
30% of patients their use was rated as ‘renally appropri-
ate’ if kidney function was assessed with
sMDRD-derived eGFR, but ‘potentially inappropriate’ by
CC (Table 3). These differences stem from a noticeable
disagreement between estimation of renal function with
different formulas and only moderate agreement in CKD
staging based on Cockcroft-Gault and sMDRD equations
[45]. While kidney function in clinical practice is usually
assessed with sMDRD or CKD-EPI glomerular filtration
rate estimates, most manufacturers’ recommendations
on drug dosage adjusting were developed based on CC
calculated with the Cockcroft-Gault equation. Greater
discrepancies between sMDRD and CC were observed
in women, disabled (activities in daily living ≤4 pts), and
subjects aged 80 years or older [46]. The discrepancies in
CKD staging based on different formulas have been rec-
ognized to result in inappropriate dosing of renally ex-
creted drugs [47–49].
Limitations
There are several limitations to our analysis. First, the
data from the PolSenior study did not comprise informa-
tion about prescribers. Some medications could be pre-
scribed by specialists against official recommendations
for special conditions, e.g. spironolactone in patients
with CKD and congestive heart failure. In such situa-
tions use of drugs with renal recommendations requires
special attention and monitoring, but should not be
Table 6 Prevalence of hyperkalaemia among subjects taking 1–4 drugs increasing serum potassium level (angiotensin-converting
enzyme inhibitors + angiotensin II receptor blockers + aldosterone antagonists + potassium-sparing diuretics + potassium-
containing agents)
No. of drugs CC sMDRD
< 60ml/min ≥ 60 ml/min < 60ml/min/1.73m2 ≥ 60 ml/min/1.73m2
1; n (%) of subjects with hyperkalaemia 102/669 (15.26)* & 73/952 (7.67) & 73/391 (18.67)# & 102/1230 (8.29)
2; n (%) of subjects with hyperkalaemia 57/258 (22.09)* 22/248 (8.87) 52/180 (28.89)# 27/326 (8.28)
3; n (%) of subjects with hyperkalaemia 14/54 (25.93) 13/51 (25.49) 14/30 (46.67)# 13/75 (17.33)
4; n (%) of subjects with hyperkalaemia 1/1 (100) 0/33 (0) 1/1 (100) 0/3 (0)
*p < 0.05 vs. patients with CC ≥ 60ml/min
#p < 0.05 vs. patients with sMDRD ≥60 ml/min/1.73m2
&p < 0.05 for chi-square test for trend for number of drugs
sMDRD short Modification of Diet in Renal Disease study equation; CC Creatinine clearance calculated with Cockcroft-Gault equation
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classified as a treatment error. Therefore, we may only
discuss the frequency of use of drugs with renal recom-
mendations, or “potentially inappropriate” drug use, and
the actual risk associated with inappropriate use may be
lower. Some other drugs that should not be used in per-
sons with impaired kidney function, especially some
NSAIDs, are available over the counter, and may be used
by patients without, or even against, their doctor’s rec-
ommendations. Second, the PolSenior study was per-
formed in the years 2007–2011. The recommendations
for many drugs use, e.g., metformin have changed since
that time. Other medications, such as rivaroxaban, dabi-
gatran, pregabalin, levetiracetam, or memantine, were
not available in Poland at that time, or they were very
expensive, and not used in everyday practice. Drugs with
renal recommendations which were not used on a regu-
lar basis, especially antibiotics, were not included in our
analysis. Next, for the reason of methodology issues, we
did not analyze the doses of drugs with renal recommen-
dations. Thus, the doses of renally cleared drugs might
have been actually adjusted to patients’ renal function.
However, this limitation does not refer to drugs that
should be avoided in patients with a certain level of
renal impairment. Finally, the list of medications chosen
for analysis, and levels of renal impairment, may be
questioned. The conflicting recommendations for dosing
of renally cleared drugs from various sources have been
recognized [50]. The lack of clear, handy guidelines for
drug dosing in older patients with renal impairment may
be a major obstacle to reduce the prevalence of inappro-
priate prescriptions.
Conclusions
Potentially inappropriate use of drugs, that is the use of
drugs that should be avoided in patients with renal impair-
ment, medications requiring dose adjustment, and poten-
tially inappropriate combinations of drugs (concomitant
use of drugs increasing risk of pre-renal kidney injury, or
concurrent use of several drugs resulting in potassium re-
tention) was a common problem in community-dwelling
PolSenior population. Method of kidney function assess-
ment may influence the prevalence of potentially inappro-
priate use of such drugs. Assessment of kidney function
with sMDRD-derived eGFR may result in overlooking of
recommended dose adjustment formulated based on cre-
atinine clearance.
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